ANIX reports net loss narrowed and $13.9 million cash

ANIX said its net loss narrowed year-over-year as R&D and G&A expenses declined. The company reported cash and investments of $13.9 million expected to fund operations for at least twelve months, with clinical progress in cancer vaccine and CAR-T programs.